ALAlbrecht Lommatzsch

Albrecht Lommatzsch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Albrecht Lommatzsch has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Macular Neovascularization Architecture in Age-Related Macular Degeneration on Treatment Requirement During the First 5 Years of Treatment

    by Michael Grün, Kai Rothaus, Martin Ziegler, Alexander Beger, Albrecht Lommatzsch, Clemens Lange, Henrik Faatz

    Background: To investigate baseline MNV characteristics in Optical Coherence Tomography Angiography (OCTA) and its impact on therapeutic needs and visual acuity after 5 years in initially therapy-naïve eyes. Methods: A retrospective study of 43 therapy-naïve eyes with neovascular AMD (nAMD). OCTA was performed at baseline and all eyes were observed for 5 years. MNV architecture was characterized by area, total vessel length, flow density and fractal dimension. These variables were tested for correlation with the number of administered intravitreal injections (IVIs) and best-corrected visual outcome (BCVA) after 5 years of treatment. Results: Mean follow-up time was 4.97 ± 0.21 years. Area and total vessel length of MNVs were significantly associated with a higher number of administered IVIs after 5 years (p < 0.05), flow density significantly correlated with fewer IVIs (p < 0.05). Fractal dimension showed a tendency to more IVIs (p = 0.056) after 5 years. Flow density at baseline correlated with a better BCVA (p < 0.05). In contrast, MNV area size, total vessel length and fractal dimension did not show any correlation to BCVA after 5 years (p > 0.05). Conclusions: Specific features of MNV architecture such as area, total vessel length and flow density can predict long-term treatment requirement and visual outcome. Further studies using deep learning algorithms are necessary to explore the usage of these findings in daily practice.

  • Altersbedingte Makuladegeneration – Teil 2: therapeutische Optionen bei der AMD

    by Albrecht Peter Lommatzsch, Henrik Faatz

    Bis zur Einführung der intravitrealen Anti-VEGF-Therapie im Jahr 2006 war eine langfristige Visusverbesserung mit den bis dahin bestehenden Behandlungsmethoden nicht erreicht worden. Dieser Beitrag gibt einen Überblick über die gegenwärtigen Behandlungsmethoden der frühen und intermediären altersbedingten Makuladegeneration (AMD), der exsudativen AMD und den therapeutischen Ansätzen bei geografischer Atrophie. Currently, intravitreal anti-VEGF therapy is the only way to maintain function with continuous monitoring in neovascular AMD. Several robust morphological biomarkers, such as intraretinal and subretinal fluid, are important to guide treatment decisions at baseline and during the course of the disease. Higher concentrations of anti-VEGF agents and the development of bispecific antibodies combining anti-VEGF and anti-angiopoietin-2 antibodies have been shown to prolong the duration of action in pivotal trials. In particular, a longer duration of action may improve patient adherence by reducing the treatment burden. Several ranibizumab biosimilars are also approved and available for the treatment of neovascular AMD. In addition, bevacizumab is now approved in its originator form for the treatment of neovascular AMD in Europe. For the treatment of geographic atrophy, the intravitreal complement inhibitors approved in the US are not approved in Europe. With these drugs, continuous monthly or bimonthly injections were associated with significantly slower growth of the atrophic area in registration studies. Visual function after two years of treatment showed no difference compared to untreated eyes. In a post-hoc analysis of the largest supplementation studies AREDS and AREDS2, a significantly slower increase in RPE atrophy from the atrophic edge to the fovea was observed compared to placebo (AREDS [n = 208]: p = 0.012; AREDS2 [n = 392]: p = 0.011). This effect needs to be confirmed in controlled randomised trials. Article published online: 13 October 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Open Access

    Adherence to Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration

    by Frank G. Holz, Focke Ziemssen, Ulrike Bauer-Steinhusen, Joachim Wachtlin, Markus Schürks, Katrin Lorenz, Paula Scholz, Tobias Machewitz, Christine Rech, Ines Lanzl, et al.


  • Open Access

    Morphology of Macular Neovascularization in Age-Related Macular Degeneration Influences Treatment Requirement and Visual Outcome After 1 Year

    by Michael Grün, Kai Rothaus, Martin Ziegler, Albrecht Lommatzsch, Clemens Lange, Henrik Faatz

    Background/Objectives: To evaluate the potential of Optical Coherence Tomography (OCT) and OCT angiography parameters in predicting treatment requirements and visual outcomes after one year in therapy-naïve eyes with neovascular age-related macular degeneration (nAMD). Methods: A retrospective study of 96 therapy-naïve eyes newly diagnosed with nAMD was carried out. All eyes received baseline OCT and OCTA. Follow-up OCT after initial upload was then carried out, involving three intravitreal injections (IVIs) with anti-Vascular Endothelial Growth Factor (anti-VEGF) at four-week intervals. OCT parameters, including intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelium detachment (PED), and central retinal thickness (CRT), were assessed qualitatively and quantitatively. Macular Neovascularization (MNV) morphology at baseline was described in terms of area, total vessel length, flow density, and fractal dimension. OCT and OCTA parameters were correlated with best corrected visual acuity (BCVA) and number of administered IVIs after 1 year of treatment. Results: Eyes with persistent subretinal fluid (SRF) or both intraretinal fluid (IRF) and SRF after upload showed a significantly higher need for IVIs (p < 0.01). Also, pigment epithelium detachment (PED) presence at baseline (p < 0.05), PED height at baseline (p < 0.01), PED presence after upload (p < 0.01), and PED height after upload (p < 0.01) were each correlated with a greater number of IVIs. Decrease in PED height during upload was accompanied by a lower number of IVIs (p < 0.01). All the aforementioned parameters had no influence on BCVA after 1 year (p > 0.05). Baseline central retinal thickness (CRT) was linked to worse BCVA at 12 months (p < 0.05), but not the number of IVIs. Follow-up CRT correlated with worse BCVA (p < 0.01) and more IVIs (p < 0.01), while CRT decrease was associated with better BCVA (p < 0.05) and fewer IVIs (p < 0.01) at 1 year. In OCTA, area and total vessel length of MNVs were correlated with BCVA after 1 year (p < 0.01) but had no influence on number of IVIs (p > 0.05). Flow density had no influence on either outcome parameter (p > 0.05). Fractal dimension was associated with BCVA (p < 0.01) and number of IVIs (p < 0.05) after 1 year. Conclusions: MNV area, vessel length, and fractal dimension in OCTA, along with fluid distribution in OCT at baseline and after follow-up, may serve as indicators of treatment needs and visual outcomes after one year. Further studies with longer observation periods and the use of deep learning models are needed to improve analyses and to verify the applicability of these findings to clinical practice.

  • Altersbedingte Makuladegeneration – Teil 2: therapeutische Optionen bei der AMD

    by Albrecht Peter Lommatzsch, Henrik Faatz

    Bis zur Einführung der intravitrealen Anti-VEGF-Therapie im Jahr 2006 war eine langfristige Visusverbesserung mit den bis dahin bestehenden Behandlungsmethoden nicht erreicht worden. Dieser Beitrag gibt einen Überblick über die gegenwärtigen Behandlungsmethoden der frühen und intermediären altersbedingten Makuladegeneration (AMD), der exsudativen AMD und den therapeutischen Ansätzen bei geografischer Atrophie. Currently, intravitreal anti-VEGF therapy is the only way to maintain function with continuous monitoring in neovascular AMD. Several robust morphological biomarkers, such as intraretinal and subretinal fluid, are important to guide treatment decisions at baseline and during the course of the disease. Higher concentrations of anti-VEGF agents and the development of bispecific antibodies combining anti-VEGF and anti-angiopoietin-2 antibodies have been shown to prolong the duration of action in pivotal trials. In particular, a longer duration of action may improve patient adherence by reducing the treatment burden. Several ranibizumab biosimilars are also approved and available for the treatment of neovascular AMD. In addition, bevacizumab is now approved in its originator form for the treatment of neovascular AMD in Europe. For the treatment of geographic atrophy, the intravitreal complement inhibitors approved in the US are not approved in Europe. With these drugs, continuous monthly or bimonthly injections were associated with significantly slower growth of the atrophic area in registration studies. Visual function after two years of treatment showed no difference compared to untreated eyes. In a post-hoc analysis of the largest supplementation studies AREDS and AREDS2, a significantly slower increase in RPE atrophy from the atrophic edge to the fovea was observed compared to placebo (AREDS [n = 208]: p = 0.012; AREDS2 [n = 392]: p = 0.011). This effect needs to be confirmed in controlled randomised trials. Article published online: 21 May 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Open Access

    Faricimab bei vorbehandelter neovaskulärer altersabhängiger Makuladegeneration (nAMD)

    by Britta Heimes-Bussmann, Rooschanak Bellenbaum, Christian Njoo, Sandra Liakopoulos, Steffen Schmitz-Valckenberg, Max Zortel, Kai Rothaus, Jost Leemhuis, Peter Mussinghoff, Albrecht Lommatzsch

    Zusammenfassung: Hintergrund: Faricimab wurde als erster bispezifischer Antikörper 9/2022 zur Behandlung der neovaskulären altersabhängigen Makuladegeneration (nAMD) und einer Visusbeeinträchtigung infolge eines diabetischen Makulaödems oder eines retinalen Venenverschlusses in der EU zugelassen. Das Wirkprofil von Faricimab wurde bislang hauptsächlich unter pivotalen klinischen Phase-3-Studienbedingungen bei therapienaiven Patienten mit nAMD untersucht. Die prospektive, multizentrische, nichtinterventionelle Studie (NIS) PASSENGER trägt dazu bei, die Wirksamkeit, Sicherheit und den Einfluss von Faricimab auf die Lebensqualität bei vorbehandelten Patienten mit nAMD unter Real-World-Bedingungen in Deutschland besser zu verstehen. Methodik: Die geplante Beobachtungsdauer pro Patient beträgt 24 Monate. Eingeschlossen werden Patienten (n = 620) ≥ 50 Jahre mit nAMD, die maximal 12 Wochen vor Studieneinschluss auf Faricimab umgestellt wurden, zuvor maximal 36 Monate mit einem vaskulären endothelialen Wachstumsfaktor(VEGF)-Inhibitor behandelt wurden und zu Therapiebeginn mit Faricimab eine bestkorrigierte Sehschärfe (BCVA) von 30 bis 80 Buchstaben auf der ETDRS-Skala aufweisen. Primärer Studienendpunkt ist die BCVA-Veränderung gegenüber dem Ausgangswert nach 52 Wochen. Zudem werden die zentrale Netzhautdicke, intraretinale, subretinale und subpigmentepitheliale Flüssigkeit im Zeitverlauf sowie patientenberichtete Parameter, Adhärenz und unerwünschte Ereignisse erfasst. Ergebnis: Der erste Patient wurde im Juni 2023 eingeschlossen. Der aktuelle Zeitplan sieht die Rekrutierung (24 Monate) bis Juni 2025 und die letzte Visite des letzten Patienten für Q2/2027 vor. Diskussion: Die Daten der PASSENGER-Studie sollen zum besseren Verständnis des Therapiemanagements im Praxisalltag in Deutschland beitragen. Graphic


  • Altersbedingte Makuladegeneration – Teil 2: therapeutische Optionen bei der AMD

    by Albrecht Peter Lommatzsch, Henrik Faatz

    Bis zur Einführung der intravitrealen Anti-VEGF-Therapie im Jahr 2006 war eine langfristige Visusverbesserung mit den bis dahin bestehenden Behandlungsmethoden nicht erreicht worden. Dieser Beitrag gibt einen Überblick über die gegenwärtigen Behandlungsmethoden der frühen und intermediären altersbedingten Makuladegeneration (AMD), der exsudativen AMD und den therapeutischen Ansätzen bei geografischer Atrophie. Currently, intravitreal anti-VEGF therapy is the only way to maintain function with continuous monitoring in neovascular AMD. Several robust morphological biomarkers, such as intraretinal and subretinal fluid, are important to guide treatment decisions at baseline and during the course of the disease. Higher concentrations of anti-VEGF agents and the development of bispecific antibodies combining anti-VEGF and anti-angiopoietin-2 antibodies have been shown to prolong the duration of action in pivotal trials. In particular, a longer duration of action may improve patient adherence by reducing the treatment burden. Several ranibizumab biosimilars are also approved and available for the treatment of neovascular AMD. In addition, bevacizumab is now approved in its originator form for the treatment of neovascular AMD in Europe. For the treatment of geographic atrophy, the intravitreal complement inhibitors approved in the US are not approved in Europe. With these drugs, continuous monthly or bimonthly injections were associated with significantly slower growth of the atrophic area in registration studies. Visual function after two years of treatment showed no difference compared to untreated eyes. In a post-hoc analysis of the largest supplementation studies AREDS and AREDS2, a significantly slower increase in RPE atrophy from the atrophic edge to the fovea was observed compared to placebo (AREDS [n = 208]: p = 0.012; AREDS2 [n = 392]: p = 0.011). This effect needs to be confirmed in controlled randomised trials. Article published online: 19 May 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Open Access

    The Vascular Architecture of Macular Neovascularization in Age-Related Macular Degeneration as a Predictor of Therapy Requirements: A 3-Year Longitudinal Analysis

    by Michael Grün, Kai Rothaus, Martin Ziegler, Clemens Lange, Albrecht Lommatzsch, Henrik Faatz

    Background: Anti-Vascular Endothelial Growth Factor (VEGF) therapy is an effective therapy for improving and stabilizing the vision of patients with neovascular age-related macular degeneration (nAMD). However, the treatment requirements, particularly the number of intraocular injections, can vary significantly among patients. This study aimed to analyze the vascular characteristics of macular neovascularizations (MNVs) to identify potential biomarkers that could predict the required injection frequency throughout the disease course. Methods: In all patients, the initial diagnosis of nAMD was confirmed using optic coherence tomography (OCT), fluorescein angiography, and OCT angiography (OCTA). MNVs detected using OCTA were subjected to quantitative vascular analysis of their area, total vascular length (sumL), fractal dimension (FD), and flow density. These results were then correlated with the number of intravitreal anti-VEGF treatments administered during the first 3 years of treatment. Additionally, the relationship between the parameters and visual acuity progression was analyzed. Results: A total of 68 treatment-naïve eyes were included in the study, comprising 31 eyes with type 1 MNV, 19 eyes with type 2 MNV, and 18 eyes with type 3 MNV. The average MNV area at baseline was 1.11 mm2 ± 1.18 mm2, the mean total vascular length was 12.95 mm ± 14.24 mm, the mean fractal dimension was 1.26 ± 0.14, and the mean flow density was 41.19 ± 5.87. On average, patients in our cohort received 19.8 ± 8.5 intravitreal injections (IVIs). A significant correlation was found between the number of administered IVIs in the first 3 treatment years and the MNV area (p < 0.005), sumL (p < 0.005), and FD (p < 0.05), while no correlation was found with flow density. Additionally, there was no significant association between MNV type and treatment requirements, nor between MNV vascular architecture and visual acuity progression. Conclusions: The results suggest that the specific vascular structure of untreated MNV may serve as a predictor of long-term treatment demand. With the emergence of new drug classes and advancements in imaging techniques, these parameters could offer valuable insights for forecasting treatment requirements.


  • Open Access

    A post-hoc analysis of intravitreal aflibercept-treated nAMD patients from ARIES & ALTAIR: predicting treatment intervals and frequency for aflibercept treat-and-extend therapy regimen using machine learning

    by Matthias Gutfleisch, Britta Heimes-Bussmann, Sökmen Aydin, Ratko Petrovic, Alexander Loktyushin, Masahito Ohji, Kanji Takahashi, Annabelle A. Okada, Paula Scholz, Hossam Youssef, et al.

    Purpose: To predict potential treatment need during treat-and-extend (T&E) anti-vascular endothelial growth factor (VEGF) treatment in neovascular age-related macular degeneration (nAMD) using an artificial intelligence (AI) model trained using transfer learning. Methods: ARIES and ALTAIR were randomized controlled Phase 3b/4 trials assessing intravitreal aflibercept (IVT-AFL) in patients with nAMD. Following treatment initiation with three monthly injections of IVT-AFL, treatment intervals were re-assessed continuously during the study based on prespecified criteria. In this post- hoc analysis, spectral domain optical coherence tomography (SD-OCT) scans from Week (Wk) 8 and Wk 16 visits from patients treated with T&E regimens of 2 mg IVT-AFL over 2 years were utilized to predict individual treatment intervals and frequency. Automated image segmentation of the SD-OCT scans was performed, predictive models of treatment intervals and frequency were developed using machine learning or logistic regression methods, and their performance was evaluated using a fivefold cross-validation. A transfer learning technique was used to adapt existing AI models previously trained on a pro-re-nata therapy regimen to the T&E dataset. Results: In total, 205 ARIES and 112 ALTAIR patient datasets were used for training and evaluation. The following results were achieved with an AI model trained using transfer learning (for ARIES) and logistic regression (for ALTAIR). For prediction of the first treatment interval (short [< 12 weeks] or long [≥ 12 weeks]) following treatment initiation, at Visit 4 (Wk 16), the AI model achieved an area under the receiver operating characteristic curve (AUC) of 0.87 and 0.78 for ARIES and ALTAIR, respectively. For assessment of the individual frequency of IVT-AFL in the first and second study years, the model achieved an AUC of 0.84 and 0.79, respectively, for ARIES, and 0.79 and 0.78, respectively, for ALTAIR. For prediction of the last intended individual treatment interval at the end of Year 2, the AI model achieved an AUC of 0.74 and 0.77 for ARIES and ALTAIR, respectively. Conclusion: AI trained using transfer learning can be used to predict potential treatment needs for anti-VEGF treatment in nAMD based on SD-OCT scans at Wk 8 and Wk 16, supporting medical decisions on interval adjustments and optimizing individualized IVT-AFL treatment regimens.


  • Open Access

    Overview of the Use of Optical Coherence Tomography Angiography in Neovascular Age-Related Macular Degeneration

    by Henrik Faatz, Albrecht Lommatzsch

    The aim of this review is to present and discuss the use of optical coherence tomography angiography (OCTA) in age-related macular degeneration (AMD). OCTA is a non-invasive imaging procedure that gives a detailed indirect view of physiological and pathological vessels in the retina and choroid membrane. Compared with dye-based imaging, OCTA provides a segmented presentation of the individual vascular layers and plexuses, thus enabling previously unattainable differentiation and classification of pathological vascular changes within or underneath the retina. In particular, OCTA facilitates early detection of exudative macular neovascularizations (MNV) so that treatment with anti-VEGF medication can be initiated. Moreover, in the context of both screening and therapy monitoring, it is hoped that OCTA can provide more detailed data to enable greater personalization of treatment and follow-up. The image quality of OCTA is, however, susceptible to artifacts, and validation of the results by studies is required. Recent developments have shown constant improvement both in the algorithms for image calculation and avoidance of artifacts and in image quality, so the scope of OCTA will certainly expand with time.